January 07, 2025

Patient Insights on HRQOL in Chronic GVHD

Explore how cutaneous graft-versus-host disease impacts patients’ quality of life across physical, psychological, and social domains.

Conexiant

January 06, 2025

Alcohol Hepatitis: Why Females Face Higher Risks

Study reveals rising hepatitis rates in young adults, with females facing greater risks of cirrhosis and liver-related death.

Conexiant

January 06, 2025

Menopause Timing and CVD: New Findings

New research links early menopause to increased cardiovascular disease risk.

Conexiant

January 06, 2025

FDA Drafts New Pulse Oximeter Rules

"Our draft recommendations are based on the best available science to help address concerns of disparate performance of pulse oximeters based on an individual's skin pigmentation."

Conexiant

January 06, 2025

Low Birth Weight, Maternal Smoking Raise COPD Risk

‘The lowest birth weight group faced a 21% higher COPD risk,’ researchers reveal.

Conexiant

January 03, 2025

Online Recruitment Fraud: Challenges and Strategies

Explore strategies to identify and mitigate fraudulent responses in online health research, with exclusion rates reaching up to 94%.

Conexiant

January 02, 2025

Glutamatergic Drugs Reduce OCD Symptoms, Study Shows

A meta-analysis suggests that glutamatergic medications significantly reduce obsessive-compulsive disorder symptoms but calls for further research due to study limitations.

Conexiant

December 20, 2024

Long COVID Shows Five Distinct Patterns: Study

In the 2024 update, the NIH's RECOVER Initiative identified five distinct symptom patterns and new diagnostic thresholds for long COVID.

Conexiant

December 20, 2024

FDA Approves Zepbound for Sleep Apnea

Eli Lilly's Zepbound gains FDA approval as the first drug to directly treat obstructive sleep apnea in adults with obesity, potentially impacting prevalent insurance coverage barriers.

Reuters